In Vivo Analysis Services

Preclinical in vivo analysis is essential in studying advanced therapies like CAR-T cell therapy in a setting closely resembling human physiology. This provides insight into the action mechanisms and the safety and efficacy of the therapy. At Protheragen, we deliver a complete suite of services for CAR-T therapy development, encompassing preclinical in vivo analysis. Taking advantage of the technology platform, our customers all over the world can obtain tailored CAT-T preclinical in vivo assay services that are, high-quality, replicable, standardized, and trustworthy.

Overview of In Vivo Assay

Preclinical in vivo studies entail the testing of a newly developed drug in an animal model before its administration in human subjects. Through in vivo preclinical studies, CAR-T therapies may be evaluated for their therapeutic potential, enabling enhancements and optimizes to be made before commencing testing on humans.

Based on the animal models that are used, in vivo studies offer the information for:

Assessing CAR T cell function in already existing large tumors or other diseases
Tracking the dynamics of the therapy effect during therapy
Studying the interactions between CAR T cells and the immune system of the host
Evaluating the trafficking of systemically injected cells in solid tumors
Examining the toxicity of CAR T cell therapy.

Preclinical analysis of CAR-T Therapy. Fig.1 Assays for the preclinical evaluation of CAR-T cells. (Arunachalam, A. K., et al., 2024)

In Vivo Models for CAR-T Therapy Efficacy Evaluation

Immune-compromised Models

The use of mice or other animals that have impaired immune systems allows for the implantation of human tumors (xenografts) which are vital for CAR T cell assessment. Tumors can be derived from established human tumor cell lines or from tumors collected from individuals. It is important to mention that such immune-deficient models are not wiped out of all immune cells so the relative assessment of the host immune response to some degree can be done.

Immune-competent Models

Implantable tumor models involve injecting histo-compatible (syngeneic) tumor cells into the immune-competent hosts. Genetically engineered models are obtained through genetic manipulation by activation of oncogenes or inactivation of tumor-suppressor genes. Humanized models such as PBMC or HSC humanized models have been designed and utilized to advance CAR T therapy.

Our Services

Through abundant project management experience alongside superior in vivo studies services, Protheragen employs suitable animal models to execute therapeutic proof-of-concept or efficacy validation and provides therapeutic efficacy tests, safety profiling, CAR-T viability, and biodistribution analysis services.

In Vivo Efficacy Evaluation

Efficacy evaluation is the most important indicator of the wide range of drug activities.

Tumor volume measurements
Evaluation of survival analysis
Bioluminescence imaging

CAR-T Viability and Biodistribution

CAR-T's cell survival, proliferation, and long-lasting persistence
Distribution and infiltration of CAR T cells
T cell phenotype analysis (Tregs, effector, and memory T cells)

Toxicity Evaluation

Evaluation of the release of cytokines
Single or repeated dose toxicity test
Immunogenicity of immunotoxicity
In vivo tumorigenicity

Based on advanced EndureCART^TM technology platforms, we provide one-stop CAR-T therapy development services. Engage with us to experience comprehensive and precision-focused preclinical in vivo analysis services that foster invention, quicken the discovery process, and progress the creation of advanced cellular therapies, supporting to facilitate your new technologies fully to the market. If you are interested in our services and platform, feel free to get in touch with us for further information.

References

Si, Xiaohui et al. "Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models." International journal of molecular sciences 23.6 (2022): 3154.
Arunachalam, Arun K et al. "Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies." Blood reviews 68 (2024): 101241.

For research use only, not for clinical use.

Platforms

Online Inquiry

* Your Name

* Phone Number

* E-mail Address

* Services Interested

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and therapeutic services for individuals.